ENOrphanet Journal of Rare Diseases | A Nationwide Study on Psychological Symptoms in Spinal Muscular Atrophy (SMA) Patients and Their Caregivers
Date: August 30, 2026
Classification: Frontiers
Recommend:
This study reveals a strong association between the psychological health of SMA patients and their caregivers, suggesting that bidirectional psychological screening should be implemented in clinical practice, providing direct evidence for the design of future family-centered interventions.
Literature Overview
The article titled 'Psychological symptoms in individuals with Spinal Muscular Atrophy (SMA) and their caregivers – results from a nation-wide study in Germany,' published in the Orphanet Journal of Rare Diseases, systematically investigates the prevalence and associated factors of psychological symptoms among individuals with Spinal Muscular Atrophy (SMA) and their caregivers in Germany. Based on a nationwide SMA registry, the study employs standardized scales to assess psychological status in both pediatric and adult patients as well as caregivers, revealing high rates of internalizing symptoms and a significant psychological link between patients and caregivers. This study provides critical epidemiological evidence on the psychosocial burden within the rare disease community.Background Knowledge
Spinal Muscular Atrophy (SMA) is an autosomal recessive disorder caused by mutations in the SMN1 gene, leading to degeneration of spinal motor neurons and resulting in progressive muscle weakness and disability. Although recent therapies targeting SMN2 splicing modification, such as nusinersen and risdiplam, have significantly improved motor function and survival outcomes, the psychosocial burden associated with long-term survival remains inadequately assessed. Current understanding of the mental health of SMA patients and caregivers is still limited by studies with small samples, single populations, or non-standardized tools, lacking systematic, multi-center, and cross-age data. Furthermore, existing treatments primarily focus on improving motor function, while interventions for internalizing symptoms such as anxiety and depression remain insufficient. This study fills a critical research gap by systematically evaluating psychological symptoms in patients and caregivers across different SMA subtypes, motor function levels, and treatment statuses using a nationally representative sample, emphasizing the necessity of integrating psychosocial care.
Methods and Core Experiments
The study adopted a cross-sectional observational design, using data from the German national SMA registry (TREAT-NMD network), including eligible patients and their caregivers between June and September 2021. A total of 103 patients (21 children, 82 adults) completed psychological assessments, with paired data available for 67 patients and their caregivers. Psychological symptoms in children were assessed via parent-reported SDQ (Strengths and Difficulties Questionnaire), while adults and caregivers used the self-reported Mini-SCL (i.e., BSI-18) scale. The scales covered dimensions such as depression, anxiety, somatization, and behavioral problems, with clinical cutoffs defined according to German norms. The study further analyzed the associations between psychological symptoms and SMA subtypes, motor function levels (non-sitters, sitters, walkers), and current treatments (nusinersen, risdiplam), and examined symptom correlations between patients and caregivers.Key Findings and Insights
Implications and Future Directions
This study provides important evidence for multidisciplinary SMA management, emphasizing that psychosocial care should be integrated into standard treatment, particularly for adult patients and families affected by SMA type 1. Future clinical pathways should incorporate routine psychological screening using tools such as SDQ or Mini-SCL to enable early identification and referral. In drug development, evaluation of new therapies should include patient-reported psychological outcomes (PROs) alongside motor endpoints to comprehensively assess treatment value. Additionally, the study supports the development of digital psychological interventions or support groups for families to reduce caregiver burden and improve emotional well-being. In disease modeling, animal models (e.g., Smn-/Δ7 mice) should consider the influence of environmental and social interaction factors when assessing treatment effects on anxiety-like behaviors.
Conclusion
This study systematically reveals the widespread presence of internalizing psychological symptoms among individuals with Spinal Muscular Atrophy (SMA) and their caregivers, particularly pronounced in adult patients and SMA type 1 families. Although modern gene-targeted therapies have significantly improved motor function, they have not significantly reduced the prevalence of psychological symptoms, highlighting the necessity of a biopsychosocial integrated approach. The strong association between patient and caregiver mental health indicates that psychological burden is mutually transmitted within the family system, suggesting that clinical care should extend from the individual to the family unit. Routine psychological screening, early psychological support, and family-centered interventions should be incorporated into standard SMA management pathways. Future research should adopt longitudinal designs to understand the dynamic changes in psychological symptoms in relation to disease progression and treatment response. Additionally, the roles of social support, disease perception, and coping strategies in psychological adaptation should be explored to inform the development of precise psychological interventions. This study lays the foundation for a comprehensive and humanized SMA care system, advancing the paradigm shift from 'curing motor function' to 'enhancing overall quality of life'.
